Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

CVS, Aetna Win U.S. Approval for $69 Billion Merger

Reuters Staff  |  October 10, 2018

WASHINGTON (Reuters)—Pharmacy chain CVS Health Corp won U.S. antitrust approval for its $69 billion acquisition of health insurer Aetna Inc, the Justice Department said on Wednesday, paving the way for a combination the companies say can help cut soaring U.S. healthcare costs.

It is the second large recent healthcare deal to win a thumbs up from the U.S. Justice Department. The agency gave the green light to health insurer Cigna Corp’s $52 billion acquisition of the nation’s largest pharmacy benefit manager (PBM), Express Scripts Holding Co, on Sept. 17.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Shares of CVS and Aetna each rose about 1 percent on Wednesday, a day when the broader market was sharply lower, with CVS trading at $80.25 and Aetna at $206.00.

The deal was approved on condition that the companies sell Aetna’s Medicare Part D prescription drug business, the Justice department said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Aetna last month said it would sell all of its standalone prescription drug plans for the government Medicare program for Americans aged 65 and older and the disabled to WellCare Health Plans Inc, paving the way for the deal’s approval.

Without the divestiture the two companies would have owned more than a 30 percent share of the Medicare Part D drug plans, creating concern about the amount of control the new CVS would have had over the Medicare prescription drug market.

Together the two have 6.8 million members in Medicare Part D drug plans, the Justice Department said.

“The divestitures required here allow for the creation of an integrated pharmacy and health benefits company that has the potential to generate benefits by improving the quality and lowering the costs of the healthcare services that American consumers can obtain,” Makan Delrahim, head of the department’s Antitrust Division, said in a statement.

The companies have said they believe together they can improve customer health by offering more low-priced medical services in CVS’s nationwide network of pharmacies, including providing chronic disease screenings and preventive care, such as blood sugar monitoring and vaccines.

CVS also has a large PBM business.

 

Share: 

Filed under:Uncategorized Tagged with:Aetna Inc.CVS Health CorpU.S. antitrust approval

Related Articles

    CVS Health to Acquire Aetna for $69 billion

    December 4, 2017

    (Reuters)—U.S. drugstore chain operator CVS Health Corp said on Sunday it had agreed to acquire U.S. health insurer Aetna Inc. for $69 billion, seeking to tackle soaring healthcare spending through lower-cost medical services in pharmacies. This year’s largest corporate acquisition will combine one of the nation’s largest pharmacy benefits managers (PBMs) and pharmacy operators with…

    Beware Antitrust Laws When Considering Healthcare Mergers

    March 1, 2015

    Analysis of laws governing collaboration of healthcare systems, hospitals and physician practices should be done before consolidating

    Aetna, Seeking Antitrust Nod, Sells Medicare Drug Business to WellCare

    September 27, 2018

    (Reuters)—Health insurer Aetna Inc said on Thursday it will sell its standalone Medicare prescription drug plan business to WellCare Health Plans Inc as it seeks U.S. antitrust approval for a planned acquisition by CVS Health Corp. The $69 billion CVS-Aetna deal would be the second large deal this year between insurers and pharmacy benefit managers,…

    U.S. Justice Department Has Concerns about Aetna-Humana Deal

    July 9, 2016

    (Reuters)—The U.S. Department of Justice has significant concerns about Aetna Inc.’s proposed acquisition of health insurer Humana Inc., a source familiar with the situation said on Thursday, and shares of Humana fell more than 11%. Aetna’s purchase of Humana would combine two of the largest providers of Medicare Advantage plans for elderly people, and investors…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences